Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 176-180

  Wang, D S ^a   Ohdo, S ^a   Koyanagi, S ^a   Takane, H ^a   Aramaki, H ^a   Yukawa, E ^a   Higuchi, S ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; HUMAN INTERFERON; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; ANTIBODIES, BLOCKING; ANTIVIRAL AGENTS; AREA UNDER CURVE; HALF-LIFE; INTERFERON ALFA-2A; MALE; MICE; MICE, INBRED ICR;

EID: 0035165404     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.176-180.2001     Document Type: Article

References (48)

1. Evening administration of alpha interferon
2. Comparative toxicity and pathology associated with administration of recombinant HuIL-1α to animals
3. Neutralizing antibodies to interferon-alpha: Relative frequency in patients treated with different interferon preparations
4. Involvement of the kidney in catabolism of human leukocyte interferon
5. 125I-interferon alpha by isolated perfused rabbit kidney and liver
6. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2α
7. Circadian rhythm studies on BCG-induced migration of PMN in normal and adrenolectomized mice
8. Evaluation of various factors influencing the action of mouse αβ interferon on the chemiluminescence of mouse peritoneal macrophages
9. Circadian variation in an immune response in man
10. Utilization of homologous proteins to evaluate the safety of recombinant human proteins - Case study: Recombinant human interferon-gamma (rhIFN-γ)
11. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients
12. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals
13. Interferon immunogenicity: Technical evaluation of interferon-α2a
14. A phase I study of recombinant interferon-α administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer
15. Incident and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha-2a by intramuscular injection
16. Minimal antigenicity of intron A in human recipients demonstrated by three analytical methods
17. Treatment of hairy cell leukaemia with recombinant human α2-interferon
18. Possible effect of time on renal allograft rejection
19. Circadian fluctuations in the activity of phagocytic cells in blood, spleen and peritoneal cavity of mice as measured by zymosan-induced chemiluminescence
20. Circadian variations in myelosuppressive activity of interferon-α in mice: Identification of an optimal treatment time associated with reduced myelosuppressive activity
21. Circadian dependence of interferon antitumor activity in mice
22. Chronopharmacological study of interferon-α in mice
23. Interferon-α receptor expression and regulation in chronic hepatitis B virus infection
24. When Should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery
25. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon
26. Incidence, neutralizing activity and clinical significance of interferon antibodies in chronic hepatitis B patients receiving recombinant α-interferons
27. Improving the ocular to systemic ratio of topical timolol by varying the dosing time
28. Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics
29. Circadian rhythm of fever induced by interferon-α in mice
30. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice
31. Chronopharmacological study of sodium valproate in mice: Dose-concentration-response relationship
32. An influencing factor to predict plasma valproate concentrations: Circadian stage-dependent kinetics
33. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice
34. Chronopharmacological study of acetylsalicylic acid in mice
35. Circadian rhythm of embryotoxicity induced by sodium valproate in mice
36. Pharmacokinetic studies with recombinant cytokines: Scientific issues and practical considerations
37. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon
38. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients
39. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma
40. Comparative toxicity of Escherichia coli and yeast rHuIL-3 in cynomolgus and rhesus monkeys
41. Pathology induced by interleukin-6
42. Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (intron A)
43. Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
44. The role of the kidney in the metabolism of plasma proteins
45. Circadian rhythms in murine reticulo-endothelial function
46. Interferon neutralizing antibodies in a patient treated with human fibroblast interferon
47. Leucocyte-derived interferon-α in patients with antibodies to rIFNα2b
48. Detection and incidence of neutralizing antibodies to interferon-α-n1